Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Prevention Research
Cancer Prevention Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Biomarkers and Early Detection Research

Abstract A29: Ductal Carcinoma in Situ Lesions Commonly Exhibit Heterogeneity within Individuals

Zhengyu Jiang, Dana Pape-Zambito, Hong Wu, Karthik Devarajan, Carolyn M. Slater, Kathy Q. Cai, Arthur Patchefsky, Mary B. Daly and Xiaowei Chen
Zhengyu Jiang
Fox Chase Cancer Center, Philadelphia, PA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dana Pape-Zambito
Fox Chase Cancer Center, Philadelphia, PA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Wu
Fox Chase Cancer Center, Philadelphia, PA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karthik Devarajan
Fox Chase Cancer Center, Philadelphia, PA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolyn M. Slater
Fox Chase Cancer Center, Philadelphia, PA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathy Q. Cai
Fox Chase Cancer Center, Philadelphia, PA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arthur Patchefsky
Fox Chase Cancer Center, Philadelphia, PA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary B. Daly
Fox Chase Cancer Center, Philadelphia, PA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaowei Chen
Fox Chase Cancer Center, Philadelphia, PA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1940-6207.PREV-12-A29 Published November 2012
  • Article
  • Info & Metrics
Loading

Abstract

Background: Cellular heterogeneity of IHC biomarker expression between patients has been well documented in invasive ductal carcinoma (IDC) and its precursor lesion, ductal carcinoma in situ (DCIS). However, no studies have quantified the variations in the expression of standard prognostic or therapeutic response-monitoring markers within an individual patient's DCIS lesions. This intra-individual heterogeneity in DCIS likely hinders current personalized medicine strategies which largely rely on clinical results from single biopsy samples. More importantly, because current regimens are restricted to standardized IHC parameters, this bias could contribute to inadequate decision-making for risk assessment and therapeutic approaches in DCIS patients. Therefore, it is critical to quantitatively evaluate intra-individual heterogeneity of standard clinical markers in DCIS.

Experimental Design: Breast cancer cases were selected in which patients were concurrently diagnosed with DCIS. Sequential sections from paraffin embedded tissue blocks were cut and immunostained with anti-ER, -PR, -HER-2, -ki-67, -p16, -p53, and -p63 antibodies. Ten DCIS lesions from each patient were randomly selected throughout the entire tissue section derived from one or two multifocal-lesion blocks. Significant variations in IHC marker expressions were defined by a ≥20% of the lesions within an individual showing staining patterns that differ from the majority of lesions within that individual. Each case was considered to display heterogeneity among DCIS lesions when at least 2/6 of the IHC markers were classified as having significant variations in expression. Associations of case heterogeneity with clinical characteristics were examined by Fisher's exact tests.

Results: Over 2,100 scores were analyzed for 380 DCIS lesions among different patients. PR, HER-2, Ki-67, and p16 displayed significant expression variations in DCIS lesions within an individual patient in 21%, 58%, 47% and 61% of cases, respectively (p < 0.05 for PR; p < 1 × 10−8 for HER-2, Ki-67 and p16). Seventy-one percent of individuals manifested various levels of expression of at least 2/6 markers, and 32% of patients had discordant expression of at least 3/6 markers tested. These percentages were statistically greater than a hypothesized level of 10% difference within an individual (p < 1 × 10−18 and p < 0.001, respectively). Patients exhibiting a higher extent of heterogeneity (3/6 markers displaying variations in expression) were also more likely to have nodal involvement (p < 0.05). Furthermore, ER- lesions was positively correlated to PR- status and to a moderate or high Ki-67 proliferative index (p < 1 × 10−23 and p < 1 × 10−8, respectively).

Conclusions: This is the first study to quantitatively evaluate intra-individual heterogeneity of standard clinical markers in DCIS. Our results clearly support the hypothesis that intra-individual heterogeneity in multi-lesion DCIS is quite common. This is clinically relevant of basing the treatment regimen of a patient diagnosed with IDC or DCIS on these markers. A substantial amount of heterogeneity may signify that a patient is more likely to develop a resistant population of cells and to have subsequent relapse at a later date. This work was kindly supported by the FCCC Personalized Risk and Prevention Keystone, the Susan G. Komen for the Cure (KG100274), and Eileen Stein Jacoby Fund.

Citation Format: Zhengyu Jiang, Dana Pape-Zambito, Hong Wu, Karthik Devarajan, Carolyn M. Slater, Kathy Q. Cai, Arthur Patchefsky, Mary B. Daly, Xiaowei Chen. Ductal carcinoma in situ lesions commonly exhibit heterogeneity within individuals. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr A29.

  • ©2012 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Prevention Research: 5 (11 Supplement)
November 2012
Volume 5, Issue 11 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Prevention Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A29: Ductal Carcinoma in Situ Lesions Commonly Exhibit Heterogeneity within Individuals
(Your Name) has forwarded a page to you from Cancer Prevention Research
(Your Name) thought you would be interested in this article in Cancer Prevention Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A29: Ductal Carcinoma in Situ Lesions Commonly Exhibit Heterogeneity within Individuals
Zhengyu Jiang, Dana Pape-Zambito, Hong Wu, Karthik Devarajan, Carolyn M. Slater, Kathy Q. Cai, Arthur Patchefsky, Mary B. Daly and Xiaowei Chen
Cancer Prev Res November 1 2012 (5) (11 Supplement) A29; DOI: 10.1158/1940-6207.PREV-12-A29

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A29: Ductal Carcinoma in Situ Lesions Commonly Exhibit Heterogeneity within Individuals
Zhengyu Jiang, Dana Pape-Zambito, Hong Wu, Karthik Devarajan, Carolyn M. Slater, Kathy Q. Cai, Arthur Patchefsky, Mary B. Daly and Xiaowei Chen
Cancer Prev Res November 1 2012 (5) (11 Supplement) A29; DOI: 10.1158/1940-6207.PREV-12-A29
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Biomarkers and Early Detection Research

  • Abstract PR10: Identification of novel candidate serum metabolite biomarkers for distinguishing between gastro-esophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma
  • Abstract CN01-01: Big challenges of big data: Biomedical science in the petabyte era
  • Abstract CN06-03: Disease dynamics: Cancers evolving fast and slow or not at all
Show more Biomarkers and Early Detection Research

Biomarkers of Premalignant Lesions

  • Abstract A14: Finding biomarkers in the differential expression patterns between epithelial layers in cervical dysplasia
  • Abstract A13: AdipoR1 overexpression and AMPK signaling in histologically normal endometrium from obese women and in endometrial tumorigenesis
  • Abstract A10: A new in silico physical optical model (iPOM) for the study of cervical intraepithelial neoplasia
Show more Biomarkers of Premalignant Lesions

Biomarkers of Premalignant Lesions: Poster Presentations: Proffered Abstracts

  • Abstract B09: PROMOTER CPG ISLAND METHYLATION DURING PROGRESSION OF ATYPICAL HYPERPLASIA TO BREAST CANCER
  • Abstract A30: DNA methylation field defects in colorectal cancer patients.
Show more Biomarkers of Premalignant Lesions: Poster Presentations: Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Prevention Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Prevention Research
eISSN: 1940-6215
ISSN: 1940-6207

Advertisement